文献速递胃肠外科围术期管理与 ERAS

腰方肌阻滞第三型对腹腔镜胃癌根治术术后细胞免疫与镇痛效果的随机对照试验

Efficacy of quadratus lumborum block type 3 on postoperative cell-mediated immunity and analgesia for laparoscopic radical gastrectomy: a prospective randomized controlled trial.
PubMed 文献 · Surg Endosc · 2025-04-15

一项前瞻性随机对照试验将54例腹腔镜胃癌根治术患者均分两组,Q组术前接受超声引导双侧腰方肌阻滞第三型(每侧0.25%罗哌卡因30 mL)联合全麻,C组仅全麻。结果显示Q组术后CD3+、CD4+T细胞、NK细胞及CD4+/CD8+比值下降更少,静息和运动VAS评分更低,阿片类药物用量及不良反应发生率更低。

要点

  • 超声引导QLB3可减轻腹腔镜胃癌根治术围术期细胞免疫抑制。
  • QLB3改善术后镇痛并降低阿片类药物用量及不良反应发生率。
  • 研究为单中心随机对照试验,样本量54例,需谨慎外推。

核心结论

  • 对腹腔镜胃癌根治术患者,超声引导QLB3可减轻围术期细胞免疫抑制、改善术后镇痛、减少阿片类药物用量并降低不良反应发生率。

研究设计与样本

  • Q组术前接受超声引导双侧QLB3(0.25%罗哌卡因每侧30 mL)联合全麻,C组仅全麻;两组术后均使用患者自控静脉镇痛。

主要发现

  • Q组在术后0、12、24、48 h的CD3+、CD4+T细胞、NK细胞水平及CD4+/CD8+比值下降程度均小于C组(P<0.05)。
  • Q组在术后0、12、24、48 h的静息和运动VAS疼痛评分均显著低于C组(P<0.05)。
  • Q组阿片类药物用量及术后不良反应发生率均低于C组(P<0.05)。

关键数值与推荐

  • QLB3方案:超声引导下双侧注射0.25%罗哌卡因,每侧30 mL。
  • 主要结局为术前30 min及术后0、12、24、48 h的T细胞亚群和NK细胞水平。
  • 次要结局为术后0、12、24、48 h静息和运动VAS评分、阿片类药物用量及术后不良反应发生率。

临床怎么用

  • 腹腔镜胃癌根治术患者可考虑术前实施超声引导双侧QLB3以改善术后镇痛并减轻免疫抑制。
  • QLB3有助于减少术后阿片类药物用量及相关不良反应。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Various methods have been formulated to reduce pain and relieve immunosuppression in order to improve prognosis. The current study aimed to evaluate the effect of ultrasound-guided quadratus lumborum block (QLB) on the postoperative analgesia and perioperative cell-mediated immunity in patients underwent laparoscopic radical gastrectomy. PATIENTS AND METHODS: A total of 54 patients scheduled for laparoscopic radical gastrectomy were randomly evenly assigned into both groups. The participants in Group Q received US-guided QLB 3 bilaterally with ropivacaine (0.25%, 30 mL on each side) before surgery along with GA, and those in Group C received GA without any special treatment. Both groups were given patient-controlled intravenous analgesia postoperatively. The primary outcomes were the T-cell subsets and Natural killer (NK) cell level at 30 min before surgery (T0) and at 0, 12, 24, and 48 h postoperatively (T1, T2, T3, and T4) were measured. The secondary outcomes were as fellows: the visual analog scale (VAS) pain score (rest and movement) at T1, T2, T3, and T4. In addition, the opioid consumption, and the incidence of postoperative adverse reactions. RESULTS: The level of CD3 + , CD4 + T, and natural killer (NK) cells, besides the CD4 + /CD8 + ratio showed less reduction at T1, T2, T3, and T4 in Group Q (P < 0.05). The VAS pain scores (at rest and on movement) were significantly lower in Group Q at T1-T4 (P < 0.05). Opioid consumption and the incidence of adverse reactions were lower in Group Q (P < 0.05). CONCLUSION: For patients undergoing LRG, the ultrasound-guided QLB 3 could alleviate perioperative cell-mediated immunity suppression, improve postoperative analgesia, decrease opioid consumption, and reduce the incidence of adverse reactions. CLINICAL TRIAL REGISTRATION NUMBER: The Chinese Clinical Trial Registry (ChiCTR2000034592).

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Wang F, Xie T, Guo Y, et al. Efficacy of quadratus lumborum block type 3 on postoperative cell-mediated immunity and analgesia for laparoscopic radical gastrectomy: a prospective randomized controlled trial. Surg Endosc. 2025. PMID: 40232402. doi:10.1007/s00464-025-11727-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。